Today's Veterinary Practice

MAR-APR 2018

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link:

Contents of this Issue


Page 14 of 95

TRESADERM ® (thiabendazole, dexamethasone, neomycin sulfate solution) Dermatologic Solution Brief Summary: Before using TRESADERM, please consult the product insert, a summary of which follows: CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. WARNING: For topical use in dogs and cats. Avoid contact with eyes. Keep this and all drugs out of the reach of children. DESCRIPTION: TRESADERM Dermatologic Solution contains the following active ingredients in units per mL: 40mg thiabendazole, 1mg dexamethasone, 3.2mg neomycin (from neomycin sulfate); and inactive ingredients: glycerin, propylene glycol, purifi ed water, hypophosphorus acid, calcium hypophosphite, about 8.5% ethyl alcohol and about 0.5% benzyl alcohol. INDICATIONS and USAGE: TRESADERM aids in the treatment of certain bacterial, mycotic, and infl ammatory dermatoses and otitis externa in dogs and cats. The amount to apply and frequency of treatment are dependent upon the severity and extent of lesions. Five to fi fteen drops of TRESADERM should be instilled in the ear twice daily. In treating dermatoses affecting areas other than the ear, the surface of the lesions should be well moistened (2-4 drops per square inch) twice daily. The volume required will be dependent upon the size of the lesion. PRECAUTIONS: Application of TRESADERM should be limited to a period not longer than 1 week. On rare occasions, application of the product may result in erythema or discomfort in the treated area. Erythema of the treated area can last from 24 to 48 hours. When applied to fi ssured or denuded areas, transient discomfort can follow with the expression of pain usually lasting 2-5 minutes. While systemic side effects are not likely with topically applied corticosteroids, the possibility of such side effects should be considered if use is prolonged or extensive. If signs of salt and water retention or potassium excretion are noticed, such as increased thirst, weakness, lethargy, reduced urine output, gastrointestinal disturbances or increased heart rate, treatment should be discontinued and appropriate measures taken to correct the electrolyte and fl uid imbalance. The full FDA-approved product insert can be found at SiteCollectionDocuments/TRESADERM-PI.pdf. For technical assistance, to request a Safety Data Sheet or to report suspected adverse events, call 1-877-217-3543. For additional information about adverse event reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or Approved for use on dogs and cats. IMPORTANT SAFETY INFORMATION: TRESADERM is for topical use only in dogs and cats. On rare occasions, application of the product may result in erythema or discomfort in the treated area. Discomfort in the treated area can last from 24 hours to 48 hours. Merial is now part of Boehringer Ingelheim. TRESADERM ® is a registered trademark of Merial. ©2018 Merial, Inc. Duluth, GA. All rights reserved. TRE17TRADEAD (09/17). ✔ Flea Allergy Dermatitis ✔ Focal Pyoderma ✔ Otitis Externa ✔ Ringworm ✔ Hot Spots Discomfort in the treated area can last TRUST TRIPLE ACTION TRESADERM • Anti-fungal • Anti-bacterial • Anti-inflammatory TRESADERM ® Dermatologic Solution aids in the treatment of certain bacterial, mycotic, and infl ammatory dermatoses, such as:

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - MAR-APR 2018